Immune response in mildly affected COVID-19 patients last for months: Study

Researchers have found that coronavirus patients with mild symptoms develop an immune response that lasts for months and even longer, as opposed to earlier studies that suggested antibodies disappear just after recovery. study conducted in China on 349 COVID-19 patients, immune response lasted for six months regardless of illness severity. study is yet to be reviewed by peer groups, which would give it legitimacy. In a similar study conducted in United States, scientists discovered that defences created by immune system in COVID-19 patients appeared even after three months of recovery. 

Re: Fifth Billionaire Emerges From Malaysia's Glove Manufacturing Industry Amid COVID

In ar study, researchers found that COVID-19 patients are at high risk of developing some sort of mental illness within three months after getting infected. study conducted on over 62,000 COVID-19 patients found that 1 out of 16 patients developed some sort of mental illness within first three months of getting infected. study found that risk was even higher in those patients who h to be hospitalised due to severity of disease. common mental illnesses that a COVID-19 patient could experience are anxiety, depression, insomnia, etc. 

Re: Indian-origin Physician Wins Award For COVID-19 Work In UK

COVID-19 pandemic

coronavirus pandemic has been raging havoc across world for past six months and due to contagion nature of disease people have been confined inside ir homes in most parts of world, which again has been a huge factor in causing mental illnesses. According to data by Johns Hopkins University, word has recorded over 21 million confirmed cases so far, of which at least 7,74,000 people have lost ir lives. United States, Brazil, and India are top three most affected countries, with 5.4 million, 3.3 million, and 2.7 million infections respectively. 

Re: COVID-19 Vaccine: Govt Panel Meets Representatives Of Leing Domestic Manufacturers

Re: CanSi's COVID-19 Vaccine Candidate Gets First Patent; Phase III Trials Begin In Russia